Payment overview · 2025
General Payments
$1,110.88
47 reported records · 11 companies
Healthcare provider profile · identity verified
Ndudi Christopher Aniemeka, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHICAGO, IL · NPI 1255447421
Verified facts
What the public records show
CMS Open Payments records show Ndudi Christopher Aniemeka, MD received $1,110.88 in general payments during 2025 across 47 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 27.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Gemtesa by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $305.30 | 27.5% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $218.85 | 19.7% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $134.10 | 12.1% | 6 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $88.59 | 8.0% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $72.11 | 6.5% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $67.28 | 6.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.11 | 5.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.10 | 5.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.63 | 5.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.95 | 3.1% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.86 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,090.66 | 46 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $305.30 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $218.85 | 9 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $105.58 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $105.58 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $105.58 | 5 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $88.59 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $72.11 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $67.28 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $59.11 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $55.63 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.95 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.95 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.52 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 184 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 125 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 168 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 135 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 150 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
150 | 39 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
22 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
184 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
135 | 23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
168 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
227 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
61 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
213 | 27 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
125 | 15 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 972 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 566 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 374 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 283 | 37 |
| Ozempic | Semaglutide | 227 | 39 |
| Eliquis | Apixaban | 213 | 27 |
| Gabapentin | Gabapentin | 190 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 189 | 34 |
| Farxiga | Dapagliflozin Propanediol | 184 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 38 |
| Metformin Hcl Er | Metformin Hcl | 176 | 43 |
| Jardiance | Empagliflozin | 168 | 30 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 163 | 16 |
| Linzess | Linaclotide | 150 | 39 |
| Vascepa | Icosapent Ethyl | 141 | 15 |
| Carvedilol | Carvedilol | 136 | 25 |
| Kerendia | Finerenone | 135 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 132 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 129 | 37 |
| Gemtesa | Vibegron | 125 | 15 |
| Losartan Potassium | Losartan Potassium | 124 | 23 |
| Metformin Hcl | Metformin Hcl | 122 | 15 |
| Furosemide | Furosemide | 119 | 20 |
| Famotidine | Famotidine | 117 | 20 |
| Divalproex Sodium | Divalproex Sodium | 115 | 21 |
| Potassium Chloride | Potassium Chloride | 111 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 51 |
| Omeprazole | Omeprazole | 106 | 25 |
| Trazodone Hcl | Trazodone Hcl | 102 | 19 |
| Pregabalin | Pregabalin | 101 | 23 |
| Clonazepam | Clonazepam | 100 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 24 |
| Tramadol Hcl | Tramadol Hcl | 90 | 28 |
| Risperidone | Risperidone | 89 | 15 |
| Olanzapine | Olanzapine | 83 | 12 |
| Alendronate Sodium | Alendronate Sodium | 82 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 13 |
| Nifedipine Er | Nifedipine | 79 | 13 |
| Valsartan | Valsartan | 79 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 73 | 19 |
| Benztropine Mesylate | Benztropine Mesylate | 72 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 72 | 30 |
| Topiramate | Topiramate | 72 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 12 |
| Levetiracetam | Levetiracetam | 68 | suppressed |
| Lisinopril | Lisinopril | 68 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | suppressed |
| Rybelsus | Semaglutide | 61 | 13 |
| Baclofen | Baclofen | 59 | suppressed |
| Entresto | Sacubitril/Valsartan | 58 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 57 | suppressed |
| Bumetanide | Bumetanide | 56 | 15 |
| Donepezil Hcl | Donepezil Hcl | 56 | suppressed |
| Latanoprost | Latanoprost | 52 | suppressed |
| Mirtazapine | Mirtazapine | 52 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 51 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 24 |
| Metformin Er Gastric | Metformin Hcl | 49 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 49 | 24 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 49 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 48 | suppressed |
| Allopurinol | Allopurinol | 46 | suppressed |
| Spironolactone | Spironolactone | 46 | suppressed |
| Austedo Xr | Deutetrabenazine | 41 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Prednisone | Prednisone | 41 | 18 |
| Valacyclovir | Valacyclovir Hcl | 41 | suppressed |
| Belsomra | Suvorexant | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 23 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 15 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Methimazole | Methimazole | 30 | suppressed |
| Simvastatin | Simvastatin | 30 | suppressed |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 25 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Clozapine | Clozapine | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 23 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 23 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 22 | suppressed |
| Prolia | Denosumab | 22 | 15 |
| Trintellix | Vortioxetine Hydrobromide | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 20 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 19 | 16 |
| Trulicity | Dulaglutide | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Haloperidol | Haloperidol | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Aristada | Aripiprazole Lauroxil | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Fingolimod | Fingolimod Hcl | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 13 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Veozah | Fezolinetant | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,110.88 · 47 records | Bayer Healthcare Pharmaceuticals Inc. | ABRYSVO, AUSTEDO XR, CAPLYTA, COMIRNATY, FARXIGA, GEMTESA, IBSRELA, JARDIANCE, Kerendia, LINZESS, NURTEC ODT, OTEZLA, PREVNAR 20, REPATHA | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error